New scholarship opportunities for optometric residents from Euclid Vision and Visionary Optics

News
Article

Euclid Vision and Visionary Optics are offering 6 scholarships intended to support eye care providers in training.

Diverse group of students studying at library (Adobe Stock / Jacob Lund)

(Adobe Stock / Jacob Lund)

Euclid Vision Corporation has announced the Euclid 2023-2024 Resident Scholarships intended to support and recognize the efforts of forward-thinking eye care providers currently in training. The scholarships include the Tim Koch Memorial Scholarship, the George E. Glady Scholarship, and the Joann Simonsen Scholarship. Each scholarship is for $1000.

Jackson Lau, OD, FAAO, FSLS, Euclid’s senior manager of professional relations, said, “Euclid created its annual Resident Scholarship Program to encourage innovation and honor optometric residents who reflect the company’s enduring commitment to proactive myopia management.”

Visionary Optics is also offering 3 scholarships in honor of the enduring impact of Rob Breece, OD, for his revolutionary work in the modern speciality contact lens industry, and who was instrumental in initiating key advances in the field until his passing in 2009. The scholarship is intended to identify innovators in the field of speciality contact lenses and each will be for $1000.

“Through this scholarship, Visionary Optics aims to empower and inspire the next generation of specialty lens residents ensuring that Dr Breece’s legacy of ingenuity, dedication and excellence lives on,” said Lynette K. Johns, OD, FAAO, FSLS, FBCLA, Visionary Optics’ director of clinical and scientific affairs.

Application Information

Submissions for the Elucid Scholarship may include clinical case reports and series, research study projects, myopia-related presentations and lectures, business proposals for new myopia management or technology, or journal articles. Applicants must also incorporate the use of Euclid Ortho-K lenses, which will be provided in relation to the pursuit of these scholarships. The final submission deadline is May 1, 2024. More information can be found here.

For the Visionary Optics Scholarship, submissions require a case report or clinical study using VO scleral lenses – Europa (standard), Europa Ta gent, or Latitude (freeform) lenses. The final submission deadline is May 1, 2024. More information can be found here.


Recent Videos
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
A. Paul Chous, MA, OD, FAAO, details a presentation on this year's updates on diabetes given at this year's Academy meeting
© 2024 MJH Life Sciences

All rights reserved.